Merck Announces Positive New Data for ENFLONSIA for Infants and Children Under 2 Years of Age at Increased Risk for Severe Respiratory Syncytial Virus Disease Over Two RSV Seasons
Merck and Mayo Clinic Announce New Research and Development Collaboration to Support AI-Enabled Drug Discovery and Precision Medicine
Health Canada Approves KEYTRUDA SC, a subcutaneous formulation of pembrolizumab across multiple cancer indications
Health Canada Approves KEYTRUDA SC, a subcutaneous formulation of pembrolizumab across multiple cancer indications
Health Canada Approves KEYTRUDA SC, a subcutaneous formulation of pembrolizumab across multiple cancer indications
Merck Announces Health Canada Approval of ENFLONSIA® for the prevention of RSV in newborns and infants
Merck & Co., Inc., Rahway, N.J., USA Announces Fourth-Quarter and Full-Year 2025 Financial Results; Highlights Progress Advancing Broad, Diverse Pipeline
Merck Reaches Agreement With U.S. Government to Expand Access to Medicines and Lower Costs for Americans
KEYTRUDA® Plus Padcev® Significantly Improved Event-Free Survival, Overall Survival and Pathologic Complete Response Rates for Cisplatin-Eligible Patients with MIBC When Given Before and After Surgery
